Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tarun Narang

Gastroenterology Charlotte, NC Medical Doctor

NPI 1205904448 CMS profile 938573

300 Billingsley Rd, Suite 301, Charlotte, NC 28211

Open in the dashboard

General payments

$11,337

673 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tarun Narang of Charlotte, NC is reported in the CMS Open Payments database as having received $11,337 across 673 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,897 94
2024 General $1,942 91
2023 General $1,419 84
2022 General $1,976 123
2021 General $1,496 103
2020 General $1,121 75
2019 General $1,486 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarun Narang
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Tarun Narang were reported at $1,897. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Tarun Narang Gastroenterology median Middle half National median
2019 $1,486 $417 $126–$1,100 $163
2020 $1,121 $224 $74–$624 $114
2021 $1,496 $352 $106–$1,054 $132
2022 $1,976 $448 $129–$1,270 $149
2023 $1,419 $533 $150–$1,390 $160
2024 $1,942 $605 $160–$1,606 $164
2025 $1,897 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,708 169 payments
  2. Janssen Biotech, Inc. $1,120 64 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $948 60 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $852 59 payments
  5. Celgene Corporation $672 47 payments
  6. Pfizer Inc. $554 36 payments
  7. QOL Medical, LLC $543 37 payments
  8. Amgen Inc. $356 18 payments
  9. Ferring Pharmaceuticals Inc. $288 18 payments
  10. Evoke Pharma, Inc. $272 11 payments
  11. Other $3,025 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,261 670 payments
  2. Education $63 2 payments
  3. Travel and Lodging $13 1 payment
Products named General payments · program years 2019–2025
  1. HUMIRA $1,053 66 payments
  2. STELARA $805 53 payments
  3. RINVOQ $741 45 payments
  4. ENTYVIO $653 39 payments
  5. ZEPOSIA $645 45 payments
  6. XIFAXAN $549 36 payments
  7. SKYRIZI $490 29 payments
  8. CREON $449 28 payments
  9. XELJANZ $403 29 payments
  10. TREMFYA $402 16 payments
  11. Other $6,609 386 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,181

Median for Gastroenterology: 569

Drug cost

$536,648

Median for Gastroenterology: $104,976

Branded share of claims

38.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 59 $241,971
Humira Pen Adalimumab Brand 14 $97,412
Zenpep Lipase/Protease/Amylase Brand 16 $71,345
Linzess Linaclotide Brand 31 $41,581
Xifaxan Rifaximin Brand 15 $34,724
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 171 $11,448
Dexlansoprazole Dr Dexlansoprazole Brand 20 $7,271
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 42 $6,817
Mesalamine Er Mesalamine Brand 19 $5,470
Ursodiol Generic 27 $3,462

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$256,305

Medicare's payments for the services billed

Medicare patients

566

Average age 74

Services billed

3,626

301 women, 265 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 34%
Ischemic heart disease 34%
Chronic kidney disease 29%
Depression 25%
Cancer 24%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPOSIA
  • Celgene Corporation $183
$183 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $177
$177 — —
RINVOQ
  • AbbVie, Inc. $150
$150 — —
SKYRIZI
  • AbbVie, Inc. $139
$139 — —
GIMOTI
  • EVOKE PHARMA, INC. $137
$137 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

673 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record